Treatment of idiopathic interstitial pneumonias

References

• American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med.165, 277–304 (2002).
   PubMedGoogle Scholar
• Latsi PI, du Bois RM, Nicholson AG et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med.168, 531–537 (2003).
   PubMed Web of Science ®Google Scholar
• Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.168, 538–542 (2003).
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Martinez FJ. The role of pulmonary function testing in pulmonary fibrosis. Curr. Opin. Pulm. Med.6, 404–410 (2000).
   PubMedGoogle Scholar
• Jegal Y, Kim DS, Shim TS et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med.171, 639–644 (2005).
   PubMed Web of Science ®Google Scholar
• Lynch DA, David Godwin J, Safrin S et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med.172, 488–493 (2005).
   PubMed Web of Science ®Google Scholar
• Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, du Bois RM. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am. Rev. Respir. Dis.148, 1076–1082 (1993).
   PubMedGoogle Scholar
• Gay SE, Kazerooni EA, Toews GB et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med.157, 1063–1072 (1998).
   PubMed Web of Science ®Google Scholar
• Wells AU, Desai SR, Rubens MB et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med.167, 962–969 (2003).
   PubMed Web of Science ®Google Scholar
• Lama VN, Flaherty KR, Toews GB et al. Prognostic value of desaturation during a 6-min walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med.168, 1084–1090 (2003).
   PubMed Web of Science ®Google Scholar
• Lee JS, Im JG, Ahn JM, Kim YM, Han MC. Fibrosing alveolitis: prognostic implication of ground–glass attenuation at high-resolution CT. Radiology184, 451–454 (1992).
   PubMedGoogle Scholar
• Nadrous HF, Pellikka PA, Krowka MJ et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest128, 2393–2399 (2005).
   PubMed Web of Science ®Google Scholar
• Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest129, 746–752 (2006).
   PubMed Web of Science ®Google Scholar
• Hamada K, Nagai S, Tanaka S et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest131, 650–656 (2007).
   PubMed Web of Science ®Google Scholar
• King TE Jr, Safrin S, Starko KM et al. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest127, 171–177 (2005).
   PubMed Web of Science ®Google Scholar
• Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med.171, 1150–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Seibold J, Black C, Denton C et al. Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis: the BUILD 2 study [A243]. American Thoracic Society poster, 19–24 May, San Diego, CA, USA (2006).
   Google Scholar
• King TE Jr, Behr J, Brown KK et al. Build-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.177, 75–81 (2008).
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Costabel U et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med.178, 948–955 (2008).
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Safrin S, Weycker D et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med.142, 963–967 (2005).
   PubMed Web of Science ®Google Scholar
• Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J.27, 143–150 (2006).
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.171, 1040–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med.353, 2229–2242 (2005).
   PubMed Web of Science ®Google Scholar
• Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med.157, 1301–1315 (1998).
   PubMed Web of Science ®Google Scholar
• Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP 3rd. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs64, 405–430 (2004).
   PubMed Web of Science ®Google Scholar
• King TE Jr, Schwarz MI, Brown K et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am. J. Respir. Crit. Care Med.164, 1025–1032 (2001).
   PubMed Web of Science ®Google Scholar
• Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.166, 173–177 (2002).
   PubMed Web of Science ®Google Scholar
• Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest.100, 768–776 (1997).
   PubMed Web of Science ®Google Scholar
• Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR, Pierschbacher MD. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem. Pharmacol.54, 1205–1216 (1997).
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat. Med.12, 99–106 (2006).
   PubMed Web of Science ®Google Scholar
• Willis BC, Liebler JM, Luby-Phelps K et al. Induction of epithelial–mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol.166, 1321–1332 (2005).
   PubMed Web of Science ®Google Scholar
• Kim KK, Kugler MC, Wolters PJ et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA103, 13180–13185 (2006).
   PubMed Web of Science ®Google Scholar
• Reynolds HY. Lung inflammation and fibrosis: an alveolar macrophage-centered perspective from the 1970s to 1980s. Am. J. Respir. Crit. Care Med.171, 98–102 (2005).
   PubMed Web of Science ®Google Scholar
• Matsuyama W, Watanabe M, Shirahama Y et al. Activation of discoidin domain receptor 1 on CD14-positive bronchoalveolar lavage fluid cells induces chemokine production in idiopathic pulmonary fibrosis. J. Immunol.174, 6490–6498 (2005).
   PubMed Web of Science ®Google Scholar
• Borok Z, Buhl R, Grimes GJ et al. Effect of glutathione aerosol on oxidant–antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet338, 215–216 (1991).
   PubMed Web of Science ®Google Scholar
• Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am. J. Respir. Crit. Care Med.172, 417–422 (2005).
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-β1. Mol. Endocrinol.10, 1077–1083 (1996).
   PubMed Web of Science ®Google Scholar
• Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation102, 2434–2440 (2000).
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res.61, 227–237 (2004).
   PubMed Web of Science ®Google Scholar
• Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J.9, 1196–1204 (1995).
   PubMed Web of Science ®Google Scholar
• Jozsef L, Khreiss T, Fournier A, Chan JS, Filep JG. Extracellular signal-regulated kinase plays an essential role in endothelin-1-induced homotypic adhesion of human neutrophil granulocytes. Br. J. Pharmacol.135, 1167–1174 (2002).
   PubMedGoogle Scholar
• Mutsaers SE, Foster ML, Chambers RC, Laurent GJ, McAnulty RJ. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am. J. Respir. Cell Mol. Biol.18, 611–619 (1998).
   PubMed Web of Science ®Google Scholar
• Uguccioni M, Pulsatelli L, Grigolo B et al. Endothelin-1 in idiopathic pulmonary fibrosis. J. Clin. Pathol.48, 330–334 (1995).
   PubMed Web of Science ®Google Scholar
• Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet341, 1550–1554 (1993).
   PubMed Web of Science ®Google Scholar
• Saleh D, Furukawa K, Tsao MS et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am. J. Respir. Cell Mol. Biol.16, 187–193 (1997).
   PubMed Web of Science ®Google Scholar
• Trakada G, Spiropoulos K. Arterial endothelin-1 in interstitial lung disease patients with pulmonary hypertension. Monaldi Arch. Chest Dis.56, 379–383 (2001).
   PubMedGoogle Scholar
• Fraig M, Shreesha U, Savici D, Katzenstein AL. Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers. Am. J. Surg. Pathol.26, 647–653 (2002).
   PubMed Web of Science ®Google Scholar
• Davies G, Wells AU, du Bois RM. Respiratory bronchiolitis associated with interstitial lung disease and desquamative interstitial pneumonia. Clin. Chest Med.25, 717–726 (2004).
   PubMedGoogle Scholar
• Colby TV. Pathologic aspects of bronchiolitis obliterans organizing pneumonia. Chest102, S38–S43 (1992).
   PubMed Web of Science ®Google Scholar
• Cordon SM, Elborn JS, Hiller EJ, Shale DJ. C-reactive protein measured in dried blood spots from patients with cystic fibrosis. J. Immunol. Methods143, 69–72 (1991).
   PubMedGoogle Scholar
• Addis BJ, Hyjek E, Isaacson PG. Primary pulmonary lymphoma: a re-appraisal of its histogenesis and its relationship to pseudolymphoma and lymphoid interstitial pneumonia. Histopathology13, 1–17 (1988).
   PubMed Web of Science ®Google Scholar
• Vourlekis JS, Brown KK, Schwarz MI. Acute interstitial pneumonitis: current understanding regarding diagnosis, pathogenesis, and natural history. Semin. Respir. Crit. Care Med.22, 399–408 (2001).
   PubMedGoogle Scholar
• Wells AU, Hirani N. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax63(Suppl. 5), S1–S58 (2008).
   Web of Science ®Google Scholar
• Orens JB, Estenne M, Arcasoy S et al. International guidelines for the selection of lung transplant candidates: update – a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation. J. Heart Lung Transplant.25, 745–755 (2006).
   PubMed Web of Science ®Google Scholar
• Meyers BF, Lynch JP, Trulock EP, Guthrie T, Cooper JD, Patterson GA. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J. Thorac. Cardiovasc. Surg.120, 99–107 (2000).
   PubMed Web of Science ®Google Scholar
• De Meester J, Smits JM, Persijn GG, Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J. Heart Lung Transplant.20, 518–524 (2001).
   PubMed Web of Science ®Google Scholar
• Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev.CD002880 (2003).
   Google Scholar
• Raghu G, Depaso WJ, Cain K et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis.144, 291–296 (1991).
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest102, 1090–1094 (1992).
   PubMedGoogle Scholar
• Kolb M, Kirschner J, Riedel W, Wirtz H, Schmidt M. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur. Respir. J.12, 1409–1414 (1998).
   PubMedGoogle Scholar
• Kondoh Y, Taniguchi H, Yokoi T et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur. Respir. J.25, 528–533 (2005).
   PubMedGoogle Scholar
• Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax44, 280–288 (1989).
   PubMed Web of Science ®Google Scholar
• Entzian P, Schlaak M, Seitzer U, Bufe A, Acil Y, Zabel P. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung175, 41–51 (1997).
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu Y, Luo W, Xi P, Yan Y. The protective effect of colchicine on bleomycin-induced pulmonary fibrosis in rats. Chin. Med. Sci. J.7, 58–60 (1992).
   PubMedGoogle Scholar
• Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med.161, 1172–1178 (2000).
   PubMed Web of Science ®Google Scholar
• Clark JG, Dedon TF, Wayner EA, Carter WG. Effects of interferon-γ on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J. Clin. Investig.83, 1505–1511 (1989).
   PubMed Web of Science ®Google Scholar
• Narayanan AS, Whithey J, Souza A, Raghu G. Effect of γ-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest101, 1326–1331 (1992).
   PubMed Web of Science ®Google Scholar
• Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med.341, 1264–1269 (1999).
   PubMed Web of Science ®Google Scholar
• Prasse A, Muller KM, Kurz C, Hamm H, Virchow JC Jr. Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Eur. Respir. J.22, 906–911 (2003).
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Bradford WZ et al. A placebo-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med.350, 125–133 (2004).
   PubMed Web of Science ®Google Scholar
• Myers JL, Lynch DA, Nicholson AG et al. Core and site readers’ interpretations of high resolution computed tomography and surgical lung biopsy in patients with idiopathic pulmonary fibrosis – INSPIRE study. ATSA567, 175 (2007).
   Google Scholar
• Nguyen L, Ward WF, Ts’ao CH, Molteni A. Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism. Proc. Soc. Exp. Biol. Med.205, 80–84 (1994).
   PubMed Web of Science ®Google Scholar
• Ward WF, Molteni A, Ts’ao CH, Hinz JM. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int. J. Radiat. Oncol. Biol. Phys.19, 1405–1409 (1990).
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther.291, 367–373 (1999).
   PubMed Web of Science ®Google Scholar
• Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med.125, 779–785 (1995).
   PubMed Web of Science ®Google Scholar
• Gahl WA, Brantly M, Troendle J et al. Effect of pirfenidone on the pulmonary fibrosis of hermansky–pudlak syndrome. Mol. Genet. Metab.76, 234–242 (2002).
   PubMed Web of Science ®Google Scholar
• Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med.159, 1061–1069 (1999).
   PubMed Web of Science ®Google Scholar
• Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med.41, 1118–1123 (2002).
   PubMed Web of Science ®Google Scholar
• Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis.139, 370–372 (1989).
   PubMed Web of Science ®Google Scholar
• Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med.156, 1897–1901 (1997).
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Araki K, Vesin C et al. Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest.96, 250–259 (1995).
   PubMed Web of Science ®Google Scholar
• Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J.7, 515–518 (1994).
   PubMed Web of Science ®Google Scholar
• Freeburn RW, Armstrong L, Millar AB. Cultured alveolar macrophages from patients with idiopathic pulmonary fibrosis (IPF) show dysregulation of lipopolysaccharide-induced tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) inductions. Eur. Cytokine Netw.16, 5–16 (2005).
   PubMedGoogle Scholar
• Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN. Enhanced IL-1β and tumor necrosis factor-α release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J. Immunol.150, 4188–4196 (1993).
   PubMed Web of Science ®Google Scholar
• Magro CM, Allen J, Pope-Harman A et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am. J. Clin. Pathol.119, 556–567 (2003).
   PubMed Web of Science ®Google Scholar
• Chambers RC. Role of coagulation cascade proteases in lung repair and fibrosis. Eur. Respir. J.44(Suppl.), S33–S35 (2003).
   Google Scholar
• Kubo H, Nakayama K, Yanai M et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest128, 1475–1482 (2005).
   PubMed Web of Science ®Google Scholar
• Raghu G, Freudenberger TD, Yang S et al. High prevalence of abnormal acid gastro–oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J.27, 136–142 (2006).
   PubMed Web of Science ®Google Scholar
• Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.158, 1804–1808 (1998).
   PubMed Web of Science ®Google Scholar
• Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest129, 794–800 (2006).
   PubMed Web of Science ®Google Scholar
• Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur. Respir. J.30(4), 715–721 (2007).
   PubMed Web of Science ®Google Scholar
• Nadrous HF, Pellikka PA, Krowka MJ et al. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest128, S616–S617 (2005).
   Google Scholar
• Yang S, Hoffman C, Mulligan K, Spada M, Raghu C. Pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis when listed for lung transplantation and at lung transplantation. Proc. Am. Thorac. Soc.3, A369 (2006).
   Google Scholar
• Agarwal R, Gupta D, Verma JS, Aggarwal AN, Jindal SK. Noninvasive estimation of clinically asymptomatic pulmonary hypertension in idiopathic pulmonary fibrosis. Indian J. Chest Dis. Allied Sci.47, 267–271 (2005).
   PubMedGoogle Scholar
• Nathan SD, Shlobin OA, Ahmad S et al. Serial measures of pulmonary artery pressures in patients with idiopathic pulmonary fibrosis Chest128, S168 (2005).
   Google Scholar
• Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest131, 657–663 (2007).
   PubMed Web of Science ®Google Scholar
• Lederer DJ, Arcasoy SM, Barr RG et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: a UNOS/OPTN database analysis. Am. J. Transplant6, 2436–2442 (2006).
   PubMedGoogle Scholar
• Channick RN, Hoch RC, Newhart JW, Johnson FW, Smith CM. Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis. Am. J. Respir. Crit. Care Med.149, 811–814 (1994).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet360, 895–900 (2002).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Ghofrani HA, Schmehl T et al.; German PPH study group. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. Ann. Intern. Med.132, 435–443 (2000).
   PubMed Web of Science ®Google Scholar
• Madden BP, Allenby M, Loke TK, Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul. Pharmacol.44, 372–376 (2006).
   PubMed Web of Science ®Google Scholar
• Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest131, 897–899 (2007).
   PubMed Web of Science ®Google Scholar
• Gunther A, Enke B, Markart P et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur. Respir. J.29, 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Bastida G, Nos P, Aguas M et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther.22, 775–782 (2005).
   PubMed Web of Science ®Google Scholar
• Paoluzi OA, Pica R, Marcheggiano A et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment. Pharmacol. Ther.16, 1751–1759 (2002).
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum.54, 3962–3970 (2006).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med.354, 2655–2666 (2006).
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis – a retrospective analysis. Rheumatology46, 442–445 (2007).
   PubMed Web of Science ®Google Scholar
• Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology45, 1005–1008 (2006).
   PubMed Web of Science ®Google Scholar
• Guerry-Force ML, Muller NL, Wright JL et al. A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease. Am. Rev. Respir. Dis.135, 705–712 (1987).
   PubMedGoogle Scholar
• Moon J, du Bois RM, Colby TV, Hansell DM, Nicholson AG. Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease. Thorax54, 1009–1014 (1999).
   PubMed Web of Science ®Google Scholar
• Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin. Proc.64, 1373–1380 (1989).
   PubMed Web of Science ®Google Scholar
• Carrington CB, Gaensler EA, Coutu RE, FitzGerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N. Engl. J. Med.298, 801–809 (1978).
   PubMed Web of Science ®Google Scholar
• Epler GR. Bronchiolitis obliterans organizing pneumonia. Arch. Intern. Med.161, 158–164 (2001).
   PubMedGoogle Scholar
• King TE Jr. Bronchiolitis. In: Interstitial Lung Disease, 3rd Edition. Schwarz MI, King TE (Eds). BC Decker, Hamilton, ON, Canada, 645–684 (1998).
   Google Scholar
• Wells AU. Cryptogenic organizing pneumonia. Semin. Respir. Crit. Care Med.22, 449–460 (2001).
   PubMedGoogle Scholar
• Lazor R, Vandevenne A, Pelletier A, Leclerc P, Court-Fortune I, Cordier JF. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d’Etudes et de Recherche sur les Maladles “Orphelines” Pulmonaires (GERM”O”P). Am. J. Respir. Crit. Care Med.162, 571–577 (2000).
   PubMed Web of Science ®Google Scholar
• Costabel U, Teschler H, Schoenfeld B et al. BOOP in Europe. Chest102, S14–S20 (1992).
   Google Scholar
• Koss MN, Hochholzer L, Langloss JM, Wehunt WD, Lazarus AA. Lymphoid interstitial pneumonia: clinicopathological and immunopathological findings in 18 cases. Pathology19, 178–185 (1987).
   PubMed Web of Science ®Google Scholar
• Strimlan CV, Rosenow EC 3rd, Weiland LH, Brown LR. Lymphocytic interstitial pneumonitis. Review of 13 cases. Ann. Intern. Med.88, 616–621 (1978).
   PubMedGoogle Scholar
• Dufour V, Wislez M, Bergot E, Mayaud C, Cadranel J. Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy. Clin. Infect. Dis.36, E127–E130 (2003).
   PubMed Web of Science ®Google Scholar
• Suh GY, Kang EH, Chung MP et al. Early intervention can improve clinical outcome of acute interstitial pneumonia. Chest129, 753–761 (2006).
   PubMed Web of Science ®Google Scholar
• Haubitz M, Schellong S, Gobel U et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum.41, 1835–1844 (1998).
   PubMedGoogle Scholar
• Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest132, 1652–1658 (2007).
   PubMed Web of Science ®Google Scholar
• Flaherty KR, King TE Jr, Raghu G et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med.170, 904–910 (2004).
   PubMed Web of Science ®Google Scholar